Newsletter | February 26, 2019

02.26.19 -- Solutions To Today's Biomanufacturing Challenges

What you don't know about Thermo Fisher's capabilities in clinical research, cold chain, and biologics.
 
What you don't know about Thermo Fisher's capabilities in manufacturing and biologics. | View web version
 
     
 
Special Edition
 
     
     
  News from THERMO FISHER SCIENTIFIC
     
     
     
 
Biologics Manufacturing
 
Thermo Fisher Receives Commercial Licenses for Two Biologic Therapies
 
 
In 2018, the Pharma Services biologics business within Thermo Fisher Scientific, supported the commercialization of two new therapeutics for its clients. The St. Louis, Missouri and the Groningen, Netherlands sites both completed FDA Pre-Approval Inspections (PAIs) and received Establishment Inspection Reports (EIRs) for the commercial manufacture of biologic therapies.
 
 
 
 
 
     
 
biologics
 
A Blueprint For The Future: St. Louis Expansion Doubles Biologics Production Capacity
 
 
In the spirit of providing life-changing biologics for patients, Thermo Fisher Pharma Services is proud to announce the expansion of its St. Louis, Missouri biologics facility.  The expansion will increase the company’s capacity to advance medicines to meet patients’ needs. On September 21st, 2018, Thermo Fisher Scientific hosted a public dedication event with elected officials and over 400 employees to commemorate this significant addition.
 
 
 
 
 
     
 
Biomanufacturing
 
Solutions To Today’s Biomanufacturing Challenges
 
 
Biopharmaceutical companies take on a lot of risk developing new large molecule drugs. With more complex molecules in development, changing capacity needs, uncertain forecasts and increased competition, the market demands flexibility and innovative approaches to address today’s new challenges.
 
 
 
 
 
     
 
SINGLE-USE
 
Single-Use Technology For Biologics Manufacturing In St. Louis, Missouri
 
 
Watch this video and learn about Thermo Fisher Scientific’s expansion of its biologics site in St. Louis, Missouri. The facility will be largest single-use technology CDMO in North America.
 
 
 
 
 
     
     
     
  Ensure our newsletter reaches your inbox by following these whitelist instructions. If you need to update your user profile, please visit here.

This newsletter is being sent to {{lead.Email Address}}. To cancel your subscription to the newsletter, please opt out here. You may also send an e-mail to newsletter@vertmarkets.com.

© Copyright 2018 {{my.Member_Addr}}. All rights reserved. All product names contained herein are the trademarks of their respective holders.